Guillain-Barre Syndrome Market Syndrome and Size Report to 2015: Radiant Insights, Inc

Guillain-Barre Syndrome Market Symptoms, Treatment,

Pipeline Review, H2 2015: Radiant Insights

Guillain-Barre Syndrome - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Guillain-Barre Syndrome - Pipeline Review, H2 2015', provides an overview of

the Guillain-Barre Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Guillain-Barre

Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug

target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest

updates, and featured news and press releases. It also reviews key players involved in the therapeutic

development for Guillain-Barre Syndrome and special features on late-stage and discontinued projects.

Access Full Report With TOC @ http://www.radiantinsights.com/research/guillain-barre-syndromepipeline-review-h2-2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy

areas and nearly 3,000 indications. The report is built using data and information sourced from Global

Markets Direct's proprietary databases, Company/University websites, SEC filings, investor

presentations and featured press releases from company/university sites and industry-specific third

party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the

report undergoes periodic updation following a stringent set of processes that ensures that all the

profiles are updated with the latest set of information. Additionally, processes including live news &

deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent

developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain

competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs...